Testing authority uncertainty creates direct patient safety risks when contaminated or mislabeled products reach dispensaries. Clinicians prescribing cannabis need reliable potency and purity data to guide dosing recommendations and monitor for adverse effects.
State regulatory uncertainty regarding cannabis testing authority appears to be creating gaps in product oversight and quality control. When testing protocols are unclear or inconsistent, patients may receive products with unknown contaminant levels, incorrect cannabinoid profiles, or inaccurate labeling. This regulatory ambiguity undermines the clinical predictability that medical cannabis programs are designed to provide.
“Without consistent testing oversight, we’re asking patients to be guinea pigs with products of unknown quality. I tell my patients to source only from programs with robust, transparent testing requirements.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
